ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.